Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 2/20 | 0.47 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.47 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.47 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.39 |
| ▸ | FBP1 | P09467 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mercaptopurine Anhydrous SCHEMBL10522158 | 0.87 | ADORA1 (0.37) | ADORA1 | |
| Adenine SCHEMBL580228 | 0.83 | PI4KA (0.58) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL7624128 | 0.83 | PI4KA (0.58) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL38386 | 0.83 | PI4KA (0.58) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL7746165 | 0.83 | PI4KA (0.58) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Dextrose SCHEMBL7886725 | 0.82 | PI4KA (0.56) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL3921122 | 0.81 | TRPM2 (0.49) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL11136514 | 0.81 | TRPM2 (0.49) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| Adenine SCHEMBL7996359 | 0.81 | TRPM2 (0.49) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| SCHEMBL1024249 | 0.80 | ADORA1 (0.35) | ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787681-B2 | Humanized viral vectors and methods of use thereof | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2020-09-29 | — | — | US | disclosed |
| CN-107890459-A | Adenine arabinoside monophosphate freeze-dried powder injection and preparation method thereof | 海南通用康力制药有限公司 | 2018-04-10 | — | — | CN | disclosed |
| CN-107890459-A | Adenine arabinoside monophosphate freeze-dried powder injection and preparation method thereof | 海南通用康力制药有限公司 | 2018-04-10 | — | — | CN | disclosed |
| US-20170128594-A1 | Humanized Viral Vectors and Methods of Use Thereof | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2017-05-11 | — | — | US | disclosed |
| CN-101642440-B | Vidarabine monophosphate freeze-dried powder injection for injection and preparation method thereof | 广东隆赋药业股份有限公司 | 2016-12-21 | — | — | CN | disclosed |
| CN-101642440-B | Vidarabine monophosphate freeze-dried powder injection for injection and preparation method thereof | 广东隆赋药业股份有限公司 | 2016-12-21 | — | — | CN | disclosed |
| CN-102379853-B | Vidarabine monophosphate freeze-dried powder injection and preparation method thereof | HAINAN JINRUI PHARMACEUTICAL | 2013-01-16 | — | — | CN | disclosed |
| CN-102389403-B | Freeze dried monophosphate adenine arabinoside powder injection for injection and preparation method thereof | GUANGZHOU LONGFU PHARMACEUTICAL CO LTD | 2012-11-28 | — | — | CN | disclosed |
| CN-102389403-A | Freeze dried monophosphate adenine arabinoside powder injection for injection and preparation method thereof | GUANGZHOU LONGFU PHARMACEUTICAL CO LTD | 2012-03-28 | — | — | CN | disclosed |
| CN-102379853-A | Vidarabine monophosphate freeze-dried powder injection and preparation method thereof | HAINAN JINRUI PHARMACEUTICAL | 2012-03-21 | — | — | CN | disclosed |
| WO-1994027642-A1 | HEPATOTROPIC CONJUGATES OF ANTIVIRAL DRUGS, CARRIERS THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LABORATORI BALDACCI S.P.A. (IT) | 1994-12-08 | — | — | WO | disclosed |
| EP-0624098-A1 | PROCESS OF CONJUGATION OF ANTIVIRAL NUCLEOSIDES WITH LACTOSAMINATED HUMAN ALBUMIN | LABORATORI BALDACCI Spa (IT) | 1994-11-17 | — | — | EP | disclosed |
| US-5346696-A | Recombinent Interferon | KOREA GREEN CROSS CORPORATION (KR) | 1994-09-13 | — | — | US | disclosed |
| WO-1994012218-A1 | PROCESS OF CONJUGATION OF ANTIVIRAL NUCLEOSIDES WITH LACTOSAMINATED HUMAN ALBUMIN | LABORATORI BALDACCI S.P.A. (IT) | 1994-06-09 | — | — | WO | disclosed |
| WO-1993017651-A2 | ANTIVIRAL NUCLEOSIDE ANALOGUES, THEIR PRODUCTION AND USE | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 1993-09-16 | — | — | WO | disclosed |
| EP-0544878-A1 | ASIALOGLYCOPROTEIN-CONJUGATED MEDICINAL AGENT | COREA GREEN CROSS CORPORATION (KR) | 1993-06-09 | — | — | EP | disclosed |
| WO-1992022310-A1 | ASIALOGLYCOPROTEIN-CONJUGATED MEDICINAL AGENT | LIVER RESEARCH FOUNDATION OF KOREA (KR) | 1992-12-23 | — | — | WO | disclosed |
| EP-0472595-A4 | METHOD OF TREATMENT OF HEPATITIS | US COMMERCE (US) | 1992-07-08 | — | — | EP | disclosed |
| EP-0472595-A1 | METHOD OF TREATMENT OF HEPATITIS | THE UNITED STATES OF AMERICA as represented by the Secretary UNITED STATES DEPARTMENT OF COMMERCE (US) | 1992-03-04 | — | — | EP | disclosed |
| WO-1990014079-A1 | METHOD OF TREATMENT OF HEPATITIS | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, UNITED STATES DEPARTMENT OF COMMERCE (US) | 1990-11-29 | — | — | WO | disclosed |